Drugs / Evalstotug
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05180799 | Aug 2022 → Mar 2025 overdue | melanoma, non-small cell lung carcinoma | BioAtla, Inc. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05271604 | Dec 2022 → Sep 2025 | head and neck squamous cell carcinoma, metastatic malignant neoplasm | BioAtla, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Evalstotug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05271604 ↗ |
| Known as | BA3071 | “Biological: Evalstotug (BA3071)” NCT05271604 ↗ |
| Action | Inhibit | “Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody” NCT05271604 ↗ |
| Modality | Monoclonal antibody | “Conditionally active biologic (CAB) antibody” NCT05180799 ↗ |